Until recently, peritoneal carcinomatosis from colorectal cancer was a universally fatal manifestation of this cancer. However, two innovations in treatment have improved outcome for these patients. The new surgical interventions are collectively referred to as peritonectomy procedures. During these procedures, all visible cancer is removed in an attempt to leave the patient with only microscopic residual disease. Perioperative intraperitoneal chemotherapy, the second innovation, is employed to eradicate small-volume residual disease. The intraperitoneal chemotherapy is administered in the operating room with moderate hyperthermia and is referred to as heated intraoperative intraperitoneal chemotherapy. If tolerated, additional intraperitoneal chemotherapy can be administered during the first 5 postoperative days. The use of these combined treatments, cytoreductive surgery and intraperitoneal chemotherapy, improves survival, optimizes quality of life, and maximally preserves function. This article describes the natural history of colorectal cancer with carcinomatosis, the patterns of dissemination within the peritoneal cavity, and the benefits and limitations of intraperitoneal chemotherapy. Peritonectomy procedures are defined and described. Also presented are the mechanics of delivering perioperative intraperitoneal chemotherapy and the clinical assessments used to select patients who will benefit from combined treatment. The results of combined treatment for colorectal carcinomatosis are presented.
Keywords: 5-fluorouracil; Peritonectomy; colorectal cancer; hyperthermia; intraperitoneal chemotherapy; mitomycin C; peritoneal surface malignancy.